Objective: Methylglyoxal (MGO) in a heat-sterilized conventional PD solution may damage peritoneal cells directly and/or indirectly by producing advanced glycation endproducts (AGEs). This study was conducted to (a) examine the acute effect of MGO on the peritoneum (including AGE formation) and (b) study the possible AGE suppressive effect of an anti-oxidant, sodium sulfite. Method: (1) Human serum albumin (HAS) was continuously incubated with MGO (50 mM) at 37°C for as long as 14 days and the fluorescence intensity (FI) was determined (em. 440, ex. 370). (2) Three types of test solutions – (i) saline; (ii) MGO (20 mM), and (iii) MGO with sodium sulfite (30 mM) – were administered intraperitoneally to 8-week-old rats once a day for 5 consecutive days. The parietal peritoneum was examined macroscopically on the 6th day for immunostaining of anti-AGE antibodies. Result: (1) An increase in FI of HSA was observed as a function of the incubation period in the MGO solution. (2) Prominent hypervascularity and intense immunostaining of anti-AGE Ab were noted in MGO-treated rats, whereas the macroscopic alterations were suppressed in the rats that had been treated with sodium sulfite. Conclusion: MGO-induced hypervascularity and AGE formation in the peritoneum, as well as macroscopic alterations were suppressed by sodium sulfite. This may indicate that there is a risk of MGO causing a peritoneal injury and that the therapeutic potential of an anti-oxidant for this type of injury may exist.

Keywords:
CAPD, Peritoneal damage, Advanced glycation endproducts (AGEs), Glucose degradation products (GDPs), Methylglyoxal, Sodium sulfite
1.
Nilsson-Thorell CB, Muscalu N, Andren AHG, Kjellstrand PTT, Wieslander AP: Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes. Perit Dial Int 1993;13:208–213.
2.
Wieslander AP, Kjellstrand PT, Rippe B: Heat sterilization of glucose-containing fluids for peritoneal dialysis: biological consequences of chemical alterations. Perit Dial Int 1995;15 (suppl 1):S52–60.
3.
Witowski J, Korybalska K, Wisniewska J, et al: Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000;11:729–739.
4.
Sundaraman S, Cendoroglo M, Cooker LA, et al: Effect of two-chambered bicarbonate lactate-buffered peritoneal dialysis fluids on peritoneal blood mononuclear cell and polymorphonuclear cell function in vitro. Am J Kid Dis 1997;30:680–689.
5.
Mackenzie RK, Jones S, Moseley A, et al: In vivo exposure to bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function. Am J Kid Dis 2000;35:112–121.
6.
Linden T, et al: 3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis. Perit Dial Int 1998;18:290–293.
7.
Schalkwijk CG, Posthuma N, ten Brink HJ, et al: Induction of 1,2-carbonyl compounds, intermediates in the formation of advanced glycation end-products, during heat-sterilization of glucose-based peritoneal dialysis fluids. Perit Dial Int 1999;19:325–333.
8.
Miyata T, et al: Advanced glycation and lipidoxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000;58:425–435.
9.
Nakayama M, et al: Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997;51:182–186.
10.
Honda K, et al: Accumulation of advanced glycation products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial trans 1999;14:1541–1549.
11.
Park MS, Lee HA, Chu WS, Yang DH, Hwang SD: Peritoneal accumulation of AGE and peritoneal membrane permeability. Perit Dial Int 2000;20;452–460.
12.
Inagi R, Miyata T, Yamamoto T, et al: Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: Role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 1999;463:260–264.
13.
Westwood ME, Thornalley PJ: Induction of synthesis and secretion of interleukin 1 beta in the human monocytic THP-1 cells by human serum albumins modified with methylglyoxal and advanced glycation endproducts. Immunol Lett 1996;50:17–21.
14.
Sakai A, Nakayama M, Numata M, Takeasawa S, Nakamoto M: Sodium sulfite and N-acetylcysteine: New additives to dialysate for inhibiting formation of glucose degradation products and advanced glycation end-products. Adv Perit Dial 2001;17:66–70.
15.
Yamada K, Miyahara Y, Hamaguchi K, Nakayama M, Nakano H, Nozaki O, Miura Y, Suzuki S, Tuchida H, Mimura N, Araki N, Horiuchi S: Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure. Clin Nephrol 1994;42:354–361.
16.
Nilsson-Thorell CB, Muscalu N, Andren AHG, Kjellstrand PTT, Wieslander AP: Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes. Perit Dial Int 1992;13:208–213.
17.
Tauer A, Knerr T, Niwa T, Schaub TP, Lage C, Passlick-Deetjen J, Pischetsrieder M: In Vitro formation of Nε-(carboxymethyl)lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis. Biochem Biophy Res Com 2001;280:1408–1414.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.